Fig. 2From: Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trialMRD negativity was associated with durable CR. Kaplan–Meier plot for the patients with a complete response in the ITT population, as assessed by BICR (n = 33). The starting point of the observation was from the onset of CR and MRD testing. BICR blinded independent central review, CI confidence interval, CR complete response, ITT intent-to-treat, MRD minimal residual disease, NE not evaluableBack to article page